biostudies-literatureUnknown7(16)Bassan RPediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/LL). In LAL1913 trial, the Gruppo Italiano Malattie EMatologiche dell'Adulto added pegaspargase 2000 IU/m2 to courses 1, 2, 5, and 6 of an 8-block protocol for patients aged from 18 to 65 years, with dose reductions in patients aged >55 years. Responders were risk stratified for allogeneic hematopoietic cell transplantation (HCT) or maintenance per clinical characteristics and minimal residual disease (MRD). Of 203 study patients (median age, 39.8 years), 91% achieved a complete remission. The 3-year overall survival, event-free, and disease-free survival (DFS) rates were 66.7%, 57.7%, and 63.3%, respectively, fulfilling the primaryBlood advances4448-4461https://www.ebi.ac.uk/biostudies/studies/S-EPMC10440455biostudies-literaturePegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.PMC10440455Chiaretti SDella Starza IPaoloni FGuarini APiciocchi ADe Propris MSBonifacio MFoa RMattei DCandoni AMauro EBorlenghi EDe Fabritiis PMarbello LVitale ACassibba VBassan RMessina MSantoro AElia LBocchia MRambaldi AAudisio ELatte GSpinelli OMartinelli GTrappolini SScattolin AMZappasodi PDi Bartolomeo PFazi PFracchiolla NfalsePegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial.Pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/LL). In LAL1913 trial, the Gruppo Italiano Malattie EMatologiche dell'Adulto added pegaspargase 2000 IU/m2 to courses 1, 2, 5, and 6 of an 8-block protocol for patients aged from 18 to 65 years, with dose reductions in patients aged >55 years. Responders were risk stratified for allogeneic hematopoietic cell transplantation (HCT) or maintenance per clinical characteristics and minimal residual disease (MRD). Of 203 study patients (median age, 39.8 years), 91% achieved a complete remission. The 3-year overall survival, event-free, and disease-free survival (DFS) rates were 66.7%, 57.7%, and 63.3%, respectively, fulfilling the primary2023-01-01T00:00:00Z2023 Aug2026-04-12T23:07:39.265Z2025-02-19T00:38:16.596ZS-EPMC104404553727645110.1182/bloodadvances.2022009596